Breast-conserving surgery

What it is

Breast-conserving surgery is an operation that removes the breast cancer plus a small rim of normal tissue while keeping most of the breast. It is commonly called lumpectomy, and for many people with early-stage breast cancer or ductal carcinoma in situ, it offers survival outcomes similar to mastectomy when followed by radiation therapy. The main practical point is that breast-conserving surgery usually needs postoperative radiation to lower the chance of cancer coming back in the same breast.

Other names include partial mastectomy, wide local excision, segmental mastectomy, and sometimes quadrantectomy when a larger portion is removed. The goal is to remove all visible disease with a clear surgical margin while preserving breast shape as much as possible. In India, this approach is widely used in centres that have breast surgery, pathology, and radiation oncology support, because the operation works best as part of coordinated multidisciplinary care.

A short comparison helps:

Procedure	What is removed	Breast preserved?	Radiation usually needed?
Breast-conserving surgery	Tumour + margin of normal tissue	Yes	Yes
Mastectomy	Entire breast	No	Sometimes

Breast-conserving surgery may be done with a standard technique or with oncoplastic methods, which combine cancer removal with reshaping of the breast to improve appearance after a larger excision.

How it works

The surgeon removes the cancer and a surrounding margin of healthy-looking tissue. The specimen is sent to pathology to confirm the diagnosis, measure tumour size, and check whether the margins are free of cancer cells. If cancer is found at the edge of the removed tissue, another operation may be needed to take more tissue, called re-excision.

Many patients also have surgery to assess lymph nodes in the armpit, most often a sentinel lymph node biopsy. This helps stage the cancer and guide decisions about further treatment. The exact operation depends on imaging findings, tumour size relative to breast size, whether there is one tumour or more than one area, and patient preference.

Radiation after surgery is a key part of breast-conserving therapy. Surgery removes the known tumour, while radiation treats remaining microscopic cancer cells that may still be present in the breast. This combination is why breast-conserving therapy can control cancer as effectively as mastectomy in appropriately selected patients.

Evidence and uses

Breast-conserving surgery is most often used for early-stage invasive breast cancer and ductal carcinoma in situ. It is generally considered when the tumour can be removed with clear margins and an acceptable cosmetic result. It may also be possible after neoadjuvant chemotherapy, which can shrink a larger tumour before surgery.

High-quality evidence over many years shows that, for selected patients, breast-conserving surgery followed by radiation has survival outcomes comparable to mastectomy. The trade-off is that preserving the breast usually means committing to radiation afterward and accepting a somewhat higher risk of needing another breast procedure if margins are not clear.

Common situations where it may be considered include:

1. A single small breast cancer relative to breast size.
2. Ductal carcinoma in situ confined to one area.
3. Cancer shrunk by preoperative systemic therapy.
4. Selected cases with two or three lesions in the same breast, if all can be removed with negative margins and acceptable breast shape.

Recent prospective data suggest that some patients with multiple ipsilateral breast cancers may also be candidates. In one trial highlighted by Mayo Clinic, women aged 40 years and older with two or three cancer foci in the same breast who underwent breast-conserving therapy had a 5-year local recurrence rate of 3.1%, below the prespecified 8% threshold. This does not mean every patient with multiple tumours should avoid mastectomy, but it shows that careful selection can expand options.

Breast-conserving surgery may be less suitable when there are diffuse suspicious calcifications, persistent positive margins despite re-excision, inflammatory breast cancer, inability to receive radiation, or a very large tumour relative to breast size. Some patients still choose mastectomy for personal reasons, genetic risk, anxiety about recurrence, or to avoid radiation if appropriate.

When to see a clinician

See a breast surgeon or cancer specialist if you have a new breast lump, nipple discharge, skin dimpling, nipple inversion, or an abnormal mammogram or ultrasound. If breast cancer has already been diagnosed, ask whether breast-conserving surgery is an option in your case and whether you would also need sentinel node surgery, radiation, chemotherapy, endocrine therapy, or HER2-targeted treatment.

Questions worth asking include:

• Am I a candidate for breast-conserving surgery?
• Will I need radiation afterward?
• What are the chances I may need a second surgery for margins?
• Is oncoplastic surgery available?
• How will this affect breast appearance and recovery?

In India, it is especially important to discuss access to postoperative radiation before choosing this approach, because breast-conserving surgery without the planned radiation component may not provide the same local control.

Limitations and open questions

Breast-conserving surgery is effective, but it is not the right choice for every breast cancer. Suitability depends on tumour biology, imaging, breast size, margin status, and the ability to complete radiation and follow-up. Cosmetic outcomes also vary and can be affected by the amount of tissue removed, breast size, smoking, diabetes, and wound healing.

There are still open questions about the best use of breast-conserving surgery in patients with multiple tumours in one breast, after strong responses to neoadjuvant therapy, and in different molecular subtypes. Evidence is growing, but not all groups have equally strong long-term data.

Another limitation is that pathology and imaging details matter. A patient may start with a plan for lumpectomy but later need re-excision or mastectomy if margins remain positive or if more extensive disease is found than expected. For that reason, treatment planning should be individualised and discussed in a multidisciplinary team whenever possible.